Two pharmaceutical companies share a licensing agreement to develop and co-commercialize an oncology drug in the United States and outside. The drug aims at treating a type of relapsed or refractory cancer called diffuse large B-cell lymphoma.

We leveraged Next Commercial Data Warehouse to create a comprehensive view of HCPs by unifying data across multiple siloed systems. We then devised a personalized content strategy based on HCP personas and recommended third-party channel strategies by analyzing channel constraints and HCP affinity. We designed an omnichannel marketing plan with personalized engagement journeys to move HCPs across the adoption funnel.
The customer witnessed a higher degree of conversion across various stages of the HCP funnel by adopting a personalized omnichannel approach and driving adoption within the field force
75K
Customer profiles unified
12%
Average increase in engagement index
20%
Increase in Next Best Action adoption